AZN
AstraZeneca PLC
Cash flow statement
| USDLine, in USD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 14.6B | 11.9B | 10.3B | 9.8B | 6.0B | 4.8B | 3.0B | 2.6B | 3.6B | 4.1B | 3.3B |
| 2.81B | 1.92B | 1.36B | 1.09B | 1.09B | 0.96B | 0.98B | 1.04B | 1.33B | 1.45B | 1.33B | |
| Free cash flow | 11.8B | 9.9B | 9.0B | 8.7B | 4.9B | 3.8B | 2.0B | 1.6B | 2.3B | 2.7B | 2.0B |
| Depreciation and amortization | — | — | — | 5.48B | 6.53B | 3.15B | 3.76B | 3.75B | 3.04B | 2.36B | 2.85B |
| Stock-based compensation | 719M | 660M | 579M | 619M | 615M | 277M | 259M | 219M | 220M | 241M | 211M |
| Buybacks | 521M | 81M | — | — | 149M | — | — | — | — | — | — |
| Dividends paid | 4.97B | 4.63B | 4.48B | 4.36B | 3.86B | 3.57B | 3.59B | 3.48B | 3.52B | 3.56B | 3.49B |
| Dividends per share | 3.13 | 5.94 | 5.80 | 5.80 | 5.60 | 5.60 | — | — | — | — | — |
| Free cash flow margin | 20.0% | 18.4% | 19.6% | 19.7% | 13.0% | 14.4% | 8.2% | 7.1% | 10.0% | 11.7% | 8.1% |